These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23236717)

  • 1. How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
    Ferko NC; Borisova N; Airia P; Grima DT; Thompson MF
    Manag Care; 2012 Nov; 21(11):44-52. PubMed ID: 23236717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN; Burge RT; Marshall DA; Lindsay R
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
    Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
    Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
    Berto P; Maggi S; Noale M; Lopatriello S
    Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
    Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey EV; Kanis JA
    Osteoporos Int; 2010 Mar; 21(3):495-505. PubMed ID: 19565175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
    Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
    J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R; Blackhouse G; Adachi J
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
    Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
    J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
    Jansen JP; Gaugris S; Bergman G; Sen SS
    Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
    Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
    Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
    Borgström F; Carlsson A; Sintonen H; Boonen S; Haentjens P; Burge R; Johnell O; Jönsson B; Kanis JA
    Osteoporos Int; 2006; 17(7):996-1007. PubMed ID: 16570118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.